Fig. 2
From: The synergism of SMC1A cohesin gene silencing and bevacizumab against colorectal cancer
Effects of SMC1A silencing and bevacizumab (alone or combined) in vivo. A Difference in tumor volume after SMC1A-Ov subcutaneous cell inoculation and subsequent treatment with shRNA against SMC1A and bevacizumab (alone or combined). B Kaplan–Meier estimates of overall survival. shRNA and bevacizumab improve the life span of mice and this outcome is stronger after combined treatment. C Representative images of tumors formed in the mice with SMC1A-Ov, shRNA, bevacizumab, and bevacizumab + shRNA treatment. Scale bar: 1 cm. D Example of representative histopathological examination performed with hematoxylin and eosin staining. Enlargement 500x. *p < 0.05